Submit An Article

ASX:MEM

Home
ASX:MEM

Most Read
Latest Comments

Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
- Review
- January 10, 2023
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
- Review
- June 9, 2022
PharmAust completes dosing first cohort for MND treatment, patients respond positively
- Review
- January 6, 2023
Is this the most hated company on the ASX?
- Review
- August 16, 2019

Latest Articles

- News
Memphasys Delivers Clinical Milestone as Felix™ Fertility System Clears Key Trial Benchmark
Fertility Tech Market Expands, With Memphasys Ready to Capitalise The global assisted reproductive technology (ART) sector continues to grow rapidly, with IVF cycles projected to exceed 4 million annually by 2030. The demand for technologies that improve embryo success rates is stronger than ever — and Memphasys (ASX:MEM) with its Felix™ System appears poised to
Read More
Public
- News
Memphasys Reaches Key Milestone in Felix™ Clinical Trial, Data Lock Expected Soon
Advanced Sperm Selection Technology Moves Closer to Market Memphasys Limited (ASX:MEM) has hit a critical milestone in its pivotal clinical trial for the Felix™ System, an innovative sperm selection technology designed for Assisted Reproductive Technology (ART) procedures. With the Last Patient Last Visit (LPLV) now completed, the company is entering the final phase before results
Read More
Public

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.